37 results about "Channel modulator" patented technology

Aspects of the present disclosure relate generally to systems and methods for use in the implementation and / or operation of quantum information processing (QIP) systems, and more particularly, to a double individual-addressing multi-beam Raman system for use in QIP systems. A technique is described in which a first multi-channel modulator (MCM), a first telecentric zoom lens, and a first interleaver that form a first optical path of the Raman system that receives a first array of beams and adjusts the first array of beams to individually address atomic-based qubits in a chain from a first direction. Moreover, a second MCM, a second telecentric zoom lens, and a second interleaver form a second optical path of the Raman system that receives a second array of beams and adjusts the second arrays of beams to individually address the atomic-based qubits in the chain from a second direction different from the first direction.

The invention provides a compound as shown in a formula I which can be used as a sodium channel regulator, and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition containing the compound and the stereoisomer, the tautomer or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

Provided in the present invention are a compound as represented by formula I which can be used as a sodium channel modulator, and a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition containing the compound and the stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a carrier or an excipient, and the pharmaceutical use thereof as an NaV1.8 inhibitor (against, for example, pain, respiratory diseases, neurological disorders, and mental diseases).

Provided in the present invention are a compound as represented by formula I which can be used as a sodium channel modulator, and a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition containing the compound and the stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a carrier or an excipient, and the pharmaceutical use thereof as an NaV1.8 inhibitor (against, for example, pain, respiratory diseases, neurological disorders, and mental diseases).

Provided are macrocyclic sodium channel modulators, particularly Nav1.8 channel modulators, which are compounds of Formula I, preferably Formula I1, I2, or I3, isomers, racemate, or pharmaceutically acceptable salts thereof, where the definitions of the groups and substituents are as described in the specification.

The present invention provides, inter alia, apelin receptor agonists having increased half-life, reduced desensitization, improved apelin receptor signaling properties (e.g., bias of G a signaling over arrestin signaling), enhanced stability, and / or enhanced binding to apelin receptors.

Fused heteroaryl compounds and compositions useful for preventing and / or treating a disease or condition related to aberrant function of voltage-gated sodium ion channels, e.g., an abnormal, delayed / persistent sodium current. Treatment methods for a disease or condition related to aberrant function of sodium ion channels are also provided herein, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders.

Aspects of the present disclosure relate generally to systems and methods for use in the implementation and / or operation of quantum information processing (QIP) systems, and more particularly, to a double individual-addressing multi-beam Raman system for use in QIP systems. A technique is described in which a first muti-channel modulator (MCM), a first telecentric zoom lens, and a first interleaver that form a first optical path of the Raman system that receives a first array of beams and adjusts the first array of beams to individually address atomic-based qubits in a chain from a first direction. Moreover, a second MCM, a second telecentric zoom lens, and a second interleaver form a second optical path of the Raman system that receives a second array of beams and adjusts the second arrays of beams to individually address the atomic-based qubits in the chain from a second direction different from the first direction.

Described herein, in part, are methods useful for treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as essential tremor, in a subject in need thereof, comprising administering a T-type calcium channel inhibitor in combination with at least one of propranolol, primidone, topiramate, or a pharmaceutically acceptable salt thereof. Also disclosed herein are compositions comprising the T-type calcium channel inhibitor and at least one of propranolol, primidone, topiramate, or a pharmaceutically acceptable salt thereof.

The present disclosure provides Pattern D, i.e., a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1). The present disclosure also provides pharmaceutical compositions comprising Compound 1 in the form of Pattern D, as well as methods of treating neurological and psychiatric disorders by administering to a subject in need thereof Compound 1 in the form of Pattern D or a pharmaceutical composition comprising Compound 1 in the form of Pattern D.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

Described herein, in part, are dosage forms and compositions useful for preventing and / or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

Disclosed herein are compounds of formulae (I), (II), and (III) and a pharmaceutically acceptable salts thereof. Also disclosed herein are uses of compounds of formulae (I), (II), and (III), as well as pharmaceutically acceptable salts thereof in the potential treatment or prevention of a disease or disorder which is modulated by the Kv3 potassium channels in a subject in need thereof. Also disclosed are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of a disease or disorder which is modulated by the Kv3 potassium channels.

Disclosed are therapeutic methods for treating a disease or condition characterized by decreased expression or reduced function of an ion channel using an amphotericin B derivative, or an amphotericin B derivative and an ion channel modulator. The methods can be used to treat cystic fibrosis.

Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise an azaspirononane core and left- and right-hand substitutions of the azaspirononane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.

A novel sodium channel modulator compound and its uses are presented below. The sodium channel modulator has a completely new structure as shown in formula I, and shows excellent in vitro inhibitory effect against Nav1.8. This compound or its pharmacologically acceptable salt can be used to treat sodium channel-related diseases, including diseases such as pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or arrhythmia.

The invention provides an optical chip, a laser and a light quantum computer, and the optical chip comprises a first light incoming waveguide, a second light incoming waveguide, a first beam splitter, a second beam splitter, a third beam splitter and a channel modulator. The first light incoming waveguide is used for being connected with a single light source. The two second light incoming waveguides are used for being connected with the two light sources in a one-to-one correspondence mode. The first beam splitter is in coupling connection with the first light incoming waveguide. The number of the second beam splitters is two, one input port of each second beam splitter is in coupling connection with the output port of the first beam splitter, and the other input port of each second beam splitter is in coupling connection with the second light incoming waveguide. The number of the third beam splitters is four, and the third beam splitters are coupled to the two output ports of the second beam splitter. The channel modulators are coupled to the output ports of the plurality of terminal beam splitters in a one-to-one correspondence manner. According to the technical scheme, the optical chip can be suitable for working conditions with different input light source numbers, the adaptability is improved, and the production cost is reduced.

Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise an azaspiroheptane core and left- and right-hand substitutions of the azaspiroheptane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and / or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late / persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

The present invention is directed to, in part, compositions or dosage forms comprising fused heteroaryl compounds useful for preventing and / or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late / persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, neuromuscular disorders, trigeminal autonomic cephalalgia (TAC), migraine, cranial neuropathy or multiple cranial neuropathy, and cortical spreading depression (CSD)are also provided herein. In another aspect, the present invention provides a method of making ion channel modulators.

Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise an azaspiroheptane core and left- and right-hand substitutions of the azaspiroheptane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.

This application relates to the pharmaceutical field, and specifically to a multi-TRP ion channel modulator, its preparation method, and its application. The multi-TRP ion channel modulator developed in this application can inhibit TRPV1, activate TRPM8, and activate TRPA1, and can be used to treat functional gastrointestinal disorders, intestinal mucosal damage, intestinal inflammation, immune dysregulation, gut microbiota imbalance, gastrointestinal tumors, pain, or peripheral neuritis.

We provide formulations of ion channel modulators. [Solution] The present invention partially relates to compositions or dosage forms comprising condensed heteroaryl compounds useful for preventing and / or treating diseases or conditions associated with abnormal function of voltage-gated sodium ion channels, such as abnormal delayed / persistent sodium currents. Methods for treating diseases or conditions associated with abnormal function of sodium ion channels, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, neuromuscular disorders, trigeminal-autonomic headache (TAC), migraines, cranial nerve disorders or polycranial nerve disorders, and cortical spreading depression (CSD), are also provided herein. In another aspect, the present invention provides methods for producing ion channel modulators.

Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise a diazaspiroheptane core and left- and right-hand substitutions of the diazaspiroheptane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.

Provided, in part, are compounds of Formula I:pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with the activity of sodium channels. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and / or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late / persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

The application discloses a use of patchouli oil or patchouli alcohol in preparation of a TRP channel modulator. The patchouli oil or patchouli alcohol has a function of regulating a TRP channel, and particularly has a synergistic effect with a TRPM2 inhibitor in anti-inflammatory effect, and is a promising TRPM2 inhibitor. In addition, the patchouli alcohol or patchouli oil has a function of improving colitis-related injury, and can inhibit expression of IL-1beta, TNF-alpha, IL-6, TRPM2, TRPM6 and TRPM7 genes.